NCT04824651

Covid-19 Vaccine Cohort in Specific Populations

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 6,920 (estimated)
• Sponsor: ANRS, Emerging Infectious Diseases · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Multicentre national cohort study with prospective data collection and biological specimen collection. Ancillary study in this cohort : pediatric cohort with participants from 5 to 17 years old. Enrollment complete for adult cohort. Active recruting for ancillary pediatric cohort.

Detailed description

Primary Objective 1.Evaluate in a standardized manner in each subpopulation the humoral immune response to Covid-19 vaccination at 1, 6, 12, 24 months (M) after the last dose of vaccine (1 or 2 dose schedule depending on the vaccines) and standardized assessment of the humoral response 1 month after receipt of the third injection in participants receiving a third injection as recommended Secondary objectives 1. Evaluate the cellular immune response to Covid-19 vaccination at Inclusion, 6 and 24 months after the first injection (single-injection scheme) or after the second injection of the vaccine (two or three-injections regimens) in each subpopulation 2. Compare the humoral immune response at 1, 6, 12, 24 months after the first injection (one-injection scheme) or after the second injection of vaccine (two- or three-injections regimens) of each subpopulation with a control group of subjects without the chronic diseases of interest and from any other diseases or treatment taht may have an influence on the immune response. 3. Compare the humoral immune response after 3 injections (1 month after the third dose) to that after 2 injections (1 month after the second dose) in participants with received a third injection as current recommendations 4. In each subpopulation, study the factors associated with the humoral immune response at 1 month and the persistence of the humoral immune response at 6, 12, 24 months as a function of age, stage of disease, treatments, type of vaccine (as well as characteristics specific to the subpopulations studied) 5. Evaluate and characterize the humoral immune response for participants who received a booster dose with mRNA vaccine acording to recommendations in force 6. Compare the humoral immune response between different specific subpopulations 7. Describe the seroconversion for anti-nucleoprotein antibodies 8. Immuno-virologically characterize vaccine failures (SARS-CoV2 infection) during follow-up 9. Identify genetic determinants of the immune response based on the underlying pathology and ongoing treatments if applicable (response and resistance to vaccination) Specifics secondary objectives for participants with the first dose of Astra-Zeneca vaccine and the second dose of Pfizer vaccine 1. Evaluate the humoral and the cellular immune response to Covid-19 vaccination with this vaccination schedule 2. Evaluate the clinical reaction (local and generale) after this vaccination schedule

Conditions

• Immune Deficiency

Interventions

Type	Name	Description
BIOLOGICAL	COVID-19 vaccine	Vaccination done as part of France's COVID-19 Vaccination Campaign

Timeline

• Start date: 2021-03-25
• Primary completion: 2024-06-25
• Completion: 2024-06-25
• First posted: 2021-04-01
• Last updated: 2022-02-04

Locations

3 sites across 1 country: France